Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Fragile X-associated Tremor in FMR1 Premutation Women Without FXTAS
Movement Disorders
P3 - Poster Session 3 (5:30 PM-6:30 PM)
3-013

FXTAS is a progressive neurodegenerative disorder seen in patients who carry a CGG repeat expansion premutation of 55-200 repeats in the fragile X mental retardation 1 (FMR1) gene. FXTAS is characterized by tremor, cerebellar gait ataxia, parkinsonism, and executive dysfunction starting after the age of 55.

The objective of this study was to determine whether there is a FMR1 premutation associated tremor in women who do not meet criteria for FXTAS.

 

Data from FMR1 premutation carrier women without FXTAS from two prior cross-sectional studies investigating clinical features and antisense FMR1 were included. Control women had normal FMR1 gene testing. Each woman had a FXTAS Rating Scale (FXTAS-RS) performed by a movement disorder neurologist, blinded to gene status.  Demographic features were analyzed using descriptive methods. The primary outcome measure was the total FXTAS rating scale score and secondary outcomes measures included adjustment for age, CGG size and molecular measures using linear regression. 

Data were included from 49 premutation and 22 control women: average age overall was 52±15 yrs (p=0.06), larger CGG1 repeat size in premutation carriers was 68.6±31 (p<0.001) and 68 women (68.57%, p<0.001) had a family history of fragile X syndrome. In the premutation women, FMR1 splice was increased at 5.6 (IQR=9.9, p<0.001), ASFMR1 increased at 2.8±2.1 (SD 2.1, p<0.001), and expression of FMR1 increased at 1.3±0.6 (p=0.001). There was a difference between premutation and control women in the total FXTAS-RS (7.3±5.1 vs. 4.1±2.; p=0.002).  Individual scores were increased in spiral drawing (p=0.01).

This study shows that there is an action tremor seen on spiral drawing in some FMR1 premutation women who do not meet criteria for FXTAS, which is associated with age. It is unclear if this phenotype is a forme fruste of FXTAS or whether this represents a separate tremor disorder that may or may not be neurodegenerative.  

Authors/Disclosures
Deborah Hall, MD, PhD, FAAN (Rush University)
PRESENTER
Dr. Hall has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for American Academy of Neurology. Dr. Hall has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Elsevier - Parkinsonism and Related Disorders. Dr. Hall has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Annals of Neurology. The institution of Dr. Hall has received research support from Parkinson's Foundation. The institution of Dr. Hall has received research support from CHDI. The institution of Dr. Hall has received research support from Neurocrine. The institution of Dr. Hall has received research support from Uniqure. The institution of Dr. Hall has received research support from SAGE. The institution of Dr. Hall has received research support from NIH.
Tyler Svymbersky (Rush University Medical Center) No disclosure on file
Padmaja Vittal, MD, MS (Northwestern Medicine Regional Medical Group) Dr. Vittal has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Abbvie Pharmaceuticals. Dr. Vittal has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Supernus Pharmaceuticals .
Elizabeth M. Berry-Kravis, MD, PhD (Rush University Medical Center) The institution of Dr. Berry-Kravis has received research support from NIH. The institution of Dr. Berry-Kravis has received research support from Ionis. The institution of Dr. Berry-Kravis has received research support from Zynerba. The institution of Dr. Berry-Kravis has received research support from Roche. The institution of Dr. Berry-Kravis has received research support from CDC. The institution of Dr. Berry-Kravis has received research support from FRAXA Research Foundation. The institution of Dr. Berry-Kravis has received research support from GeneTx. The institution of Dr. Berry-Kravis has received research support from Angelman Syndrome Foundation. The institution of Dr. Berry-Kravis has received research support from Acadia. The institution of Dr. Berry-Kravis has received research support from Ultragenyx. The institution of Dr. Berry-Kravis has received research support from Anavex. The institution of Dr. Berry-Kravis has received research support from Rett Syndrome Research Trust. The institution of Dr. Berry-Kravis has received research support from Ultragenyx. The institution of Dr. Berry-Kravis has received research support from Mallinckrodt. The institution of Dr. Berry-Kravis has received research support from Together Strong Foundation. The institution of Dr. Berry-Kravis has received research support from Orphazyme. The institution of Dr. Berry-Kravis has received research support from Taysha. The institution of Dr. Berry-Kravis has received research support from Erydel. The institution of Dr. Berry-Kravis has received research support from Tetra. The institution of Dr. Berry-Kravis has received research support from Neuren. The institution of Dr. Berry-Kravis has received research support from FRAXA Research Foundation.
Bichum Ouyang No disclosure on file